BG102214A - Derivatives of azetidinons for the treatment of atherosclerosis - Google Patents
Derivatives of azetidinons for the treatment of atherosclerosisInfo
- Publication number
- BG102214A BG102214A BG102214A BG10221498A BG102214A BG 102214 A BG102214 A BG 102214A BG 102214 A BG102214 A BG 102214A BG 10221498 A BG10221498 A BG 10221498A BG 102214 A BG102214 A BG 102214A
- Authority
- BG
- Bulgaria
- Prior art keywords
- alkyl
- optionally
- aryl
- value
- whichcan
- Prior art date
Links
- 201000001320 Atherosclerosis Diseases 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 10
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 150000001336 alkenes Chemical class 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical class O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229940037201 oris Drugs 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
- C07D205/085—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a nitrogen atom directly attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
- C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
- C07D205/095—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4 and with a nitrogen atom directly attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The azetidinon compounds are inhibitors of the LpPLA2 enzymeand can find application for the treatment of atherosclerosis.They have the formulawhere R1 & R2 which can be the same or different, are selectedseparately from hydrogen, halogen or C(1-8) alkyl; R4 & R5 whichcan be the same or different, are selected separately fromhydrogen, C(1-6)alkyl, C(2-6) alkenyl, aryl, aryl C(1-4)alkyl andheteroaryl C(1-4)alkyl, each of which can optionally besubstituted, or R4 & R5 can be bound together forming theremaining part of C(3-7) gycloalkyl ring; X is direct bond; thegroup X1(CH2)m where X1 is CO, CONR6, COO, CONR6CO or CONR60,where R6 is hydrogen or (C1-C6) alkyl and m has the value of 0 oris multiple having the value of from 1 to 12; the group (X1)aX2,where a has the value of 0 or 1, and X2 is C(1-12) alkylene chain,broken and/or discontinued in neighbourhood with Y by one or moreX3 groups selected from 0, S(0)x, NR6, alkene or alkyn group,where x has the value of 0, 1 or 2 or the C(1-12) alkylene chain,optionally discontinued by X1; Y is optionally substituted arylgroup; Z is oxygen, and R3 is C(1-8) alkyl, C(3-8) cycloalkyl,C(3-8) cyclo-alkyl C(1-6) alkyl, heteroalkyl,heteroalkyl-C(1-4)alkyl, aryl or aryl C(1-4)alkyl, each of whichcan optionally be substituted, or Z is S(0)n where n has the valueof 0, 1 or 2, and R3 is heteroaryl or heteroaryl C(1-4)alkyl, eachof which can optionally be substututed.22 claims
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9513442.5A GB9513442D0 (en) | 1995-07-01 | 1995-07-01 | Novel compounds |
| GBGB9515056.1A GB9515056D0 (en) | 1995-07-22 | 1995-07-22 | Novel compounds |
| GBGB9515206.2A GB9515206D0 (en) | 1995-07-25 | 1995-07-25 | Novel compounds |
| GBGB9516985.0A GB9516985D0 (en) | 1995-08-18 | 1995-08-18 | Novel compounds |
| GBGB9525132.8A GB9525132D0 (en) | 1995-12-08 | 1995-12-08 | Novel compounds |
| GBGB9608651.7A GB9608651D0 (en) | 1996-04-26 | 1996-04-26 | Novel compounds |
| GBGB9608650.9A GB9608650D0 (en) | 1996-04-26 | 1996-04-26 | Novel compounds |
| PCT/EP1996/002765 WO1997002242A1 (en) | 1995-07-01 | 1996-06-20 | Azetidinone derivatives for the treatment of atherosclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG102214A true BG102214A (en) | 1998-08-31 |
Family
ID=27562921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG102214A BG102214A (en) | 1995-07-01 | 1998-01-28 | Derivatives of azetidinons for the treatment of atherosclerosis |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP0840725A1 (en) |
| JP (1) | JP2002515852A (en) |
| KR (1) | KR19990028630A (en) |
| CN (1) | CN1197452A (en) |
| AP (1) | AP728A (en) |
| AU (1) | AU708032B2 (en) |
| BG (1) | BG102214A (en) |
| BR (1) | BR9609445A (en) |
| CA (1) | CA2225627A1 (en) |
| CZ (1) | CZ422197A3 (en) |
| EA (1) | EA199800109A1 (en) |
| HU (1) | HUP9901153A3 (en) |
| IL (1) | IL122650A0 (en) |
| MA (1) | MA23922A1 (en) |
| MX (1) | MX9800186A (en) |
| NO (1) | NO976158L (en) |
| NZ (1) | NZ311684A (en) |
| OA (1) | OA10648A (en) |
| PE (1) | PE8998A1 (en) |
| PL (1) | PL324240A1 (en) |
| SK (1) | SK178497A3 (en) |
| TR (1) | TR199701762T1 (en) |
| WO (1) | WO1997002242A1 (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997021675A1 (en) * | 1995-12-08 | 1997-06-19 | Smithkline Beecham Plc | Monocyclic beta-lactame derivatives for treatment of atherosclerosis |
| AU2698697A (en) * | 1996-04-26 | 1997-11-19 | Smithkline Beecham Plc | Azetidinone derivatives for the treatment of atherosclerosis |
| GB9608649D0 (en) * | 1996-04-26 | 1996-07-03 | Smithkline Beecham Plc | Novel compounds |
| PT1686119E (en) | 2000-02-16 | 2009-10-06 | Smithkline Beecham Plc | Pyrimidine-5-one derivatives as ldl-pla2 inhibitors |
| GB0024808D0 (en) | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
| MX2009012197A (en) | 2007-05-11 | 2010-01-15 | Univ Pennsylvania | Methods of treatment of skin ulcers. |
| MX2009012188A (en) | 2007-05-11 | 2010-02-24 | Univ Jefferson | Methods of treatment and prevention of neurodegenerative diseases and disorders. |
| US8962633B2 (en) | 2007-05-11 | 2015-02-24 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
| UY33766A (en) | 2010-12-06 | 2012-06-29 | Glaxo Group Ltd | COMPOUNDS WITH PYRIMIDINONE STRUCTURE FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY Lp-PLA2 |
| EP2651403B1 (en) | 2010-12-17 | 2020-12-02 | Glaxo Group Limited | Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases |
| US20140171431A1 (en) | 2011-06-27 | 2014-06-19 | Jianhua Shen | Azole heterocyclic compound, preparation method, pharmaceutical composition and use |
| EP2739627A4 (en) | 2011-07-27 | 2015-01-21 | Glaxo Group Ltd | 2,3-dihydroimidazo[1,2-c]pyrimidin-5(1h)-one compounds use as lp-pla² inhibitors |
| UY34216A (en) | 2011-07-27 | 2013-02-28 | Glaxo Group Ltd | New compounds that inhibit the activity of Lp-PLA2 |
| WO2014114248A1 (en) | 2013-01-25 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
| KR20150108897A (en) | 2013-01-25 | 2015-09-30 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors |
| AU2014210260B2 (en) | 2013-01-25 | 2016-08-04 | Glaxosmithkline Intellectual Property Development Limited | Bicyclic pyrimidone compounds as inhibitors of Lp-PLA2 |
| WO2016012917A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
| WO2016012916A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
| EP4056571A4 (en) | 2019-11-09 | 2024-01-24 | Shanghai Simr Biotechnology Co., Ltd. | Tricyclic dihydroimidazopyrimidone derivative, preparation method therefor, pharmaceutical composition and use thereof |
| CN115304620A (en) | 2021-05-07 | 2022-11-08 | 上海赛默罗生物科技有限公司 | Pyrimidone derivatives, preparation method, pharmaceutical composition and application thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4680391A (en) * | 1983-12-01 | 1987-07-14 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
| NZ228600A (en) * | 1988-04-11 | 1992-02-25 | Merck & Co Inc | 1-(benzylaminocarbonyl)-4-phenoxy-azetidin-2-one derivatives |
| IL99658A0 (en) * | 1990-10-15 | 1992-08-18 | Merck & Co Inc | Substituted azetidinones and pharmaceutical compositions containing them |
| GB9421816D0 (en) * | 1994-10-29 | 1994-12-14 | Smithkline Beecham Plc | Novel compounds |
| AP9701007A0 (en) * | 1994-12-22 | 1997-07-31 | Smithkline Beecham Plc | Substituted azetidin-2-ones for treatment of atherosclerosis. |
-
1996
- 1996-06-20 BR BR9609445A patent/BR9609445A/en unknown
- 1996-06-20 CZ CZ974221A patent/CZ422197A3/en unknown
- 1996-06-20 PL PL96324240A patent/PL324240A1/en unknown
- 1996-06-20 TR TR97/01762T patent/TR199701762T1/en unknown
- 1996-06-20 SK SK1784-97A patent/SK178497A3/en unknown
- 1996-06-20 KR KR1019970709952A patent/KR19990028630A/en not_active Withdrawn
- 1996-06-20 EP EP96922030A patent/EP0840725A1/en not_active Withdrawn
- 1996-06-20 NZ NZ311684A patent/NZ311684A/en unknown
- 1996-06-20 AP APAP/P/1997/001161A patent/AP728A/en active
- 1996-06-20 EA EA199800109A patent/EA199800109A1/en unknown
- 1996-06-20 AU AU63050/96A patent/AU708032B2/en not_active Ceased
- 1996-06-20 HU HU9901153A patent/HUP9901153A3/en unknown
- 1996-06-20 CN CN96196661A patent/CN1197452A/en active Pending
- 1996-06-20 JP JP50477297A patent/JP2002515852A/en active Pending
- 1996-06-20 WO PCT/EP1996/002765 patent/WO1997002242A1/en not_active Ceased
- 1996-06-20 CA CA002225627A patent/CA2225627A1/en not_active Abandoned
- 1996-06-20 IL IL12265096A patent/IL122650A0/en unknown
- 1996-06-28 MA MA24298A patent/MA23922A1/en unknown
- 1996-06-28 PE PE1996000496A patent/PE8998A1/en not_active Application Discontinuation
-
1997
- 1997-12-30 NO NO976158A patent/NO976158L/en unknown
- 1997-12-31 OA OA70172A patent/OA10648A/en unknown
-
1998
- 1998-01-07 MX MX9800186A patent/MX9800186A/en unknown
- 1998-01-28 BG BG102214A patent/BG102214A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR9609445A (en) | 1999-04-06 |
| EA199800109A1 (en) | 1998-10-29 |
| WO1997002242A1 (en) | 1997-01-23 |
| CZ422197A3 (en) | 1998-06-17 |
| SK178497A3 (en) | 1998-07-08 |
| NO976158L (en) | 1998-02-25 |
| KR19990028630A (en) | 1999-04-15 |
| IL122650A0 (en) | 1998-08-16 |
| PL324240A1 (en) | 1998-05-11 |
| NZ311684A (en) | 2000-04-28 |
| JP2002515852A (en) | 2002-05-28 |
| HUP9901153A3 (en) | 1999-11-29 |
| NO976158D0 (en) | 1997-12-30 |
| AU6305096A (en) | 1997-02-05 |
| PE8998A1 (en) | 1998-03-20 |
| AU708032B2 (en) | 1999-07-29 |
| EP0840725A1 (en) | 1998-05-13 |
| TR199701762T1 (en) | 1998-05-21 |
| MX9800186A (en) | 1998-07-31 |
| CA2225627A1 (en) | 1997-01-23 |
| HUP9901153A2 (en) | 1999-08-30 |
| OA10648A (en) | 2002-09-25 |
| AP728A (en) | 1999-01-29 |
| AP9701161A0 (en) | 1998-01-31 |
| MA23922A1 (en) | 1996-12-31 |
| CN1197452A (en) | 1998-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG102214A (en) | Derivatives of azetidinons for the treatment of atherosclerosis | |
| TR199802160T2 (en) | Azetidinone derivatives for the treatment of atherosclerosis. | |
| TR199800011T1 (en) | Benzo$g] quinoline t�revleri | |
| TW359670B (en) | Process for producing quinazolin-4-one derivatives | |
| DE69325454D1 (en) | TAXOL DERIVATIVES | |
| ATE27810T1 (en) | 2-(3-IOD-2-PROPINYLOXY)-ETHANOL CARBAMATS, THEIR PRODUCTION AND USE AS ANTIMICROBIAL SUBSTANCES. | |
| AU2647495A (en) | Novel potent inducers of terminal differentiation and methods of use thereof | |
| ZA917744B (en) | Fused ring analogs of nitrogen containing nonaromatic heterocycles. | |
| IL108786A0 (en) | 4-aminopyridines, processes for their production and pharmaceutical agents containing them | |
| BR1100061A (en) | Compound, process for its preparation, composition and use | |
| EA200000431A2 (en) | New substituted dimeric compounds, a process for their preparation and pharmaceutical compositions containing them | |
| AU6148696A (en) | Methods of inhibiting pneumocystis carinii pneumonia and compounds useful therefor | |
| TR199801039T2 (en) | Method for obtaining novel phenylamide derivatives. | |
| TW334425B (en) | Annelated dihydropyridines for preparing pharmaceutical preparations | |
| HU9402444D0 (en) | Diacyl-substituted guanidine derivatives, process for producing them and pharmaceutical compositions containing them | |
| TW238304B (en) | A process for the preparation of 1-substituted-5(4H)-tetrazolinones | |
| GR3023757T3 (en) | Cyclic benzylamino, benzylamido and benzylimido derivatives as antipsychotic agents. | |
| YU59100A (en) | Process for the preparation of the pyrazolo (4,3-d) pyrimidin-7-ones-3-pyridylsulphonyl compounds and intermediates thereof | |
| MY104777A (en) | Benzoxazine dyes | |
| GB9612600D0 (en) | Chemical compounds | |
| DE69526097D1 (en) | BICYCLIC CARBOXAMIDES AS 5-HT1A RECEPTOR LIGANDS | |
| RU98112496A (en) | 5-NAPHTALIN-1-IL-1,3-DIOXANA DERIVATIVES, THEIR PRODUCTION AND THERAPEUTIC USE | |
| DE69810294D1 (en) | CALIXAREN TUBES AS CATION RECEPTORS | |
| GB9908021D0 (en) | Pharmaceutical compounds | |
| YU37902A (en) | Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and the use thereof as medicaments |